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Abstract
Background: Breast cancer is one of the most prevalent cancers in the world and more than one million women
are diagnosed leading to 410,000 deaths every year. In our previous studies new chalcone-imidazolone conjugates
were prepared and evaluated for their anticancer activity in a panel of 53 human tumor cell lines and the lead
compounds identified were 6 and 8. This prompted us to investigate the mechanism of apoptotic event.
Results: Involvement of pro-apoptotic protein (Bax), active caspase-9 and cleavage of retinoblastoma protein was
studied. Interestingly, the compounds caused upregulation of p21, check point proteins (Chk1, Chk2) and as well as
their phosphorylated forms which are known to regulate the DNA damage pathway. Increased p53BP1 foci by
immunolocalisation studies and TRF1 suggested the possible involvement of telomere and associated proteins in
the apoptotic event. The telomeric protein such as TRF2 which is an important target for anticancer therapy
against human breast cancer was extensively studied along with proteins involved in proper functioning of
telomeres.
Conclusions: The apoptotic proteins such as Bax, active caspase-9 and cleaved RB are up-regulated in the
compound treated cells revealing the apoptotic nature of the compounds. Down regulation of TRF2 and
upregulation of the TRF1 as well as telomerase assay indicated the decrease in telomeric length revealing
telomeric dysfunction and thereby controlling the rapid rate of cell proliferation. In summary, chalcone-imidazolone
conjugates displayed significant DNA damage activity particularly at telomeres and caused both apoptosis and
senescence-like growth arrest which suggested that these compounds have potential activity against breast
carcinoma.
Background
MCF-7 is estrogen responsive breast cancer cell line and
is widely used for studying compounds with anti-tumor
activity for controlling the metastatic breast cancer [1].
Apoptosis or programmed cell death is a key regulator
of growth control. With the advancement of cancer
research the importance of apoptosis was realized in the
context of response to anti-cancer compounds [2].
Unicellular organisms respond to DNA lesions by acti-
vating cell cycle check points and repair pathways, while
multicellular organisms respond differently to DNA
damage by eliminating the damaged cells through acti-
vating apoptosis. More over defects in DNA damage-
induced apoptosis contribute to tumorigenesis [3] where
as senescence is irreversible cell cycle arrest character-
ized by DNA double-strand breaks and activation of cell
cycle check point responses leading to shortening of tel-
omeres. More over, Senescence also involves expression
of proteins such as p21 and p16 and the pathways that
cause senescence will give a right path for effective can-
cer treatment [4,5].
The ends of chromosomes are protected by telomeres
and have double stranded TTAGGG repeats of many
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double stranded telomeric DNA binding regions were
bound with TRF1 and TRF2. Here TRF2 serves the pro-
tective function where as TRF1 regulates the telomeric
length in a negative manner [7,8]. Recent reports have
established TRF2 and its role in breast carcinoma [9],
and highlights the importance of TRF2 in tumorigenesis.
It was also observed that over expression of dominant
negative form of TRF2 (DN-TRF2) in human cancerous
cells caused a rapid loss of telomere leading to senes-
cence or apoptosis [10-12]. Telomeric uncapping and
replicative senescence triggers the DNA damage path-
way in eukaryotes [13]. Cells react to double strand
DNA breaks (DSBs), by initiating the DNA damage
check response which temporarily pauses cell cycle pro-
gression until the damage has been repaired. The occur-
rence of DNA damage check point relies on the
coordinated activites of the upstream kinases like ATM
and ATR, the downstream transducer kinases CHK1
and CHK2, and the mediators such as p53BP1 and
MDC1 [14-16]. The human cell cycle check point kinase
2 (Chk2) plays a vital role in the regulation of DNA
damage response resulting in cell cycle arrest, DNA
repair, apoptosis and senescence. Therefore screening
and identification of drugs that can activate the check
point proteins is considered as promising anti-cancer
strategy, particularly in cases where apoptosis is blocked,
cellular senescence can be induced as an alternative
mechanism [17].
Combretastatin (CA-4) compound contains structurally
important feature, such as 2-phenyl rings separated by 2-
carbon atom bridges and is a known inhibitor of tubulin
polymerization [18-20]. Chalcone compounds are natural
compounds isolated from edible plants and are structu-
rally similar to CA-4 compound having 2-phenyl rings
separated by 3-carbon atom bridges with inhibitory prop-
erty against tubulin polymerization [21-23]. Imidazolones
are also structurally similar to chalcones (2-phenyl rings
are separated by 3-carbon atoms with 5 membered struc-
tures). Hence we focussed our attention towards prepar-
ing chalcone-imidazolone conjugates in search of potent
anti-cancer molecules (Figure 1). Surprisingly, these con-
jugates have shown effective cytotoxicity in wide range of
cancer cell lines [24].
In our previous studies [24] we have shown that these
chalcone-imidazolone hybrids cause G2/M cell cycle
arrest at 10 μM. But surprisingly the increased concen-
tration of these conjugates to 30 μM caused accumula-
tion cells in sub G1 phase (i.e G0 phase) indicated the
apoptotic inducing nature of these conjugates. These
interesting results prompted us to investigate their effect
on the induction of DNA damage and controlling the
rate of cell proliferation in MCF-7 cells involving pro-
teins like check point proteins, telomere repeat binding
factor 2 (TRF2), p53 binding protein1(53BP1) and other
proteins associated with apoptosis. The present study
also advocates the importance of the chalcone-imidazo-
lone conjugates and its potential implication in anti-can-
cer therapy.
Results
Chalcone- imidazolone conjugates cause apoptosis in
MCF-7 cells
In order to understand the apoptosis inducing ability of
the compounds TUNEL assay was conducted. The data
revealed that DNA fragmentation was more prominent
in compound 6 treated cells rather than in the case of
the starting material TMAC (Figure 2). The apoptotic
inducing nature of the compound was further validated
by Trypan blue exclusion assay on cell viability. We
observed that compound 6 and 8 treated cells to be less
viable than control untreated cells, positive control (CA-
4) and starting material (TMAC) (Figure 3). Blebbing,
the characteristic feature of apoptosis was also clearly
observed by nuclear staining with DNA dye DAPI in
compound 6 and 8 after 24 h of compound treatment
(Figure 4).
During the process of apoptosis the up-regulation of
proapoptotic protein (Bax) occurs as an early event
which alone is sufficient to cause apoptosis [25]. MCF-7
cells do not contain endogenous caspase-3 and express
caspase-9 during apoptosis. Retinoblastoma protein is a
known and important substrate molecule that undergoes
cleavage by the action of caspases into 48 and 68 kDa
proteins [26] and ultimately leads to apoptosis. Hence
we were interested to check whether chalcone imidazo-
lone derivatives cause apoptosis by the involvement of
Bax, active caspase-9 and cleavage of RB protein. Thus
the MCF-7 cells were treated with compounds TMAC,
CA-4, 6 and 8 at 30 μM concentration for 24 h and cell
lysates were subjected to western blotting using specific
antibodies. Our results have shown pronounced up
Figure 1 Chemical structure of chalcone-imidazolone
conjugates. 6 and 8 represents chalcone-imidazolone conjugates 6
and 8.
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cleaved RB in the compound treated cells in comparison
to control untreated cells and thus confirming the apop-
totic inducing nature of the compounds (Figure 5).
Effect of Chalcone-imidazolone conjugates on DNA
damage specific proteins (p53, Chk1and Chk2) in MCF-7
cells
DNA-damaging agents cause cell cycle arrest which ulti-
mately results in apoptosis or senescence and will be
Figure 2 Effect of chalcone-imidazolone conjugates in causing
DNA fragmentation in MCF-7 cells. MCF-7 cells were treated with
compounds TMAC, CA-4, 6 and 8 at a concentration of 30 μM for a
period of 24 h. The fragmented DNA was bind to antibody
conjugated to FITC. The fluorescence was detected and imaged
using confocal microscope. Untreated control cells, were not
apoptotic and did not exhibit DNA fragmentation, where as the
apoptotic cells in the compound treated condition show green
coloured staining. The extent of apoptosis can be visualized by
green staining and depicts the extent of DNA fragmentation. Here
C denotes control untreated cells.
Figure 3 Chalcone-imidazolone conjugates cause cell death in
MCF-7 cells. Trypan blue exclusion assay showing increase of cell
death especially in conjugates 6 and 8. MCF-7 cells were treated at
30 μM concentration of TMAC, CA-4, 6 and 8 for 24 h. Each
experiment was conducted for three times. The dead cells have lost
the shiny nature and became dark blue coloured. Each experiment
was conducted for three times. The p-values was found to be P <
0.001(***) when compared to control non-treated cells.
Figure 4 Immunofluorescence studies to observe apoptotic
related morphological changes in chalcone-imidazolone
conjugates. MCF-7 cells were grown in DMEM medium with 10%
FBS for 12 h. Conjugates (6 and 8) were treated at 30 μM for 24 h
time period. The cells were then washed, fixed with 4%
paraformaldehyde, and stained with nuclear dye DAPI. The slides
were then examined by fluorescence microscopy and
photographed. Cells with signs of apoptosis (fragmented nuclei)
were observed in chalcone-imidazolone conjugates treated cells,
when compared with control, non-treated cells.
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ways [27,28]. In order to determine the involvement of
p53, p21 and p16 proteins in this event caused by chal-
cone-imidazolone conjugates, the cells were treated with
compounds (TMAC, CA-4, 6 and 8) and Western blot
analysis was carried out. The level of p53 protein was
found to be down regulated while the levels of p21 and
p16 was found to be up-regulated (Figure 6 and 12) par-
ticularly in compound 6 and 8 treated MCF-7 cells. The
decreased levels of p53 and increased senescence like
growth arrest as observed by up-regulation of p21 and
p16 proteins clearly shows the lack of involvement of
p53 in this event. Our results strongly support the exis-
tence of p53 independent pathway in senescence like
growth arrest which has been earlier reported [29].
To concretely prove the role of check point proteins
in the DNA damage, we have checked the levels of the
Chk1 and Chk2 and as well as phosphorylated forms in
the compound (6 and 8) treated cells. As expected we
found the levels of the proteins were highly upregulated
and involvement of these proteins in this damage event
was highly elucidated (Figure 7).
Effect of Chalcone-imidazolone conjugates on the
telomeric binding protein TRF2 and p53BP1in MCF-7 cells
Telomeric-binding proteins like TRF2 play a fundamen-
tal role in maintaining the stability of telomere and con-
trols DNA damage. Inhibition of TRF2 protein causes
apoptosis or senescence at cellular level [10]. Thus we
have speculated that chalcone-imidazolone compounds
(6 and 8) might have a possible role on telomeric stabi-
lity and regulate the expression of TRF2 protein. Cell
lysates were prepared after treatment of cells with com-
pounds for 24 h and subjected to western blotting using
TRF2 specific antibody. As expected we found that the
level of TRF2 was down regulated in compound 6 and 8
treated cells when compared to controls (Figure 7) and
this was further confirmed by immunofluorescence stu-
dies. We observed that control untreated cells have
shown a large number of TRF2 specific foci which were
found to be drastically decreased in the cells treated
with the compounds (Figure 8). Moreover in metaphase
spreads of compound treated cells we have observed
randomly distributed as well as fusion of TRF2 foci as
shown in (Figure 9).
Generally actively proliferating cancerous cells have
more telomerase activity. Thus we have investigated the
Figure 5 Western blot analysis of proteins related to apoptosis.
MCF-7 cells at 80% confluence were treated with 30 μM chalcone-
imidazolone conjugates for 24 h. 50 μg protein from total cell lysate
was run on 10-15% SDS-PAGE and protein expression was detected
by Western blotting. The expression of pro-apoptotic protein (Bax),
active caspase-9 and the protein that undergo cleavage during
apoptosis (Rb), the retinoblastoma protein was determined by using
anti-Bax, anti-active caspase-9 and anti Rb-cleavage specific
antibodies. b- actin was used as loading control. Here C represents
control untreated cells.
Figure 6 Western blot analysis of tumour suppressor proteins
(p53 and p21). MCF-7 cells were treated with chalcone-
imidazolone conjugates for 24 h. The total protein extracts were
prepared after 24 h and analysed with antibodies specific to tumour
suppressor proteins such as p53 and p21. b-actin was used as
loading control. The The molecular weights of p53, p21 proteins
were 53 KDa, 21 KDa respectively.
Figure 7 Effect of chalcone imidazolone conjugates on DNA
damage associated proteins. MCF-7 cells treated at 80%
confluency with conjugates TMAC, CA-4, 6 and 8 for 24 h. The total
cell lysates were harvested and analyzed by immunoblotting with
anti-Chk2, anti-Chk1, anti-phospho Chk2T
68, anti-phospho Chk1S
345
and TRF2. The molecular weights of Chk2, Chk1, Chk2T
68, Chk1S
345
and TRF2 were 61 KDa, 60 KDa, 61 KDa, 60 KDa and 65 KDa
respectively. TMAC is the starting material and CA-4 is positive
control. b-actin was used as a loading control. Western blots were
representative of three independent experiments. The expression of
Chk1, Chk2 and phosphorylated active forms of Chk2
T68 and
Chk1S
345 were found to be up-regulated and levels of telomeric
repeat binding factor 2 (TRF2) was found to be down regulated. C
represents control untreated cells.
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Page 4 of 12Figure 8 Immunofluorescence based studies of telomere repeat binding factor 2 (TRF2) after treatment with chalcone- imidazolone
conjugates. Cells were grown in 10% FBS containing medium on cover slips and treated with 30 μM concentration of chalcone imidazolone
compounds (6 and 8). TMAC, is the starting material and CA-4, is the positive control used. Cells were fixed and processed for
immunofluorescence as described in materials and methods. Images were captured in confocal microscopy. The pattern of staining changes was
also recorded. C represents control untreated cells.
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telomerase assay using cell extracts after compound
(TMAC, CA-4, 6 and 8) treatment. Control untreated
cells which serve as positive control has highest level of
telomerase activity. Telomerase activity of the control
cells is lost when the extract was heated at 85°C for 10
min. Fluorescence reading was taken as a measure of
telomerase activity. To our surprise down regulation of
telomerase activity was observed in compound 6 and 8
treated cells. Hence our data strongly supports the effect
of compounds on telomere and regulate the DNA stabi-
lity (Figure 10).
Figure 9 Effect of Chalcone-imidazolone conjugates on size and distribution of TRF2 foci in metaphase spreads. MCF-7 cells were
synchronized with nocodazole (40 ng/ml) for 6 h time period followed by compound treatment (TMAC, CA-4, 6 and 8) at 30 μM final
concentration for 24 h time period. This is followed by colchicine treatment(100 μg/m l) for 5 h and staining procedure was done with TRF2
antibody. Control represents untreated cells.
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ciated with DNA damage dependent early response fac-
tors known as p53BP1 and are the versatile index of
telomeric dysfunction [30-32]. To ascertain the possible
involvement of p53BP1 in the context of uncapped telo-
meres MCF-7 cells were treated with compounds
(TMAC, CA-4, 6 and 8) and immunofluorescence
experiments was carried out using p53BP1 specific anti-
body (Figure 11). The p53BP1 foci were found to be
large and clearly seen in compound 6 and 8 treated
cases, depicting the potential role of these compounds
as anti-cancer molecules.
Effect of Chalcone-imidazolone conjugates on telomeric
genes in MCF-7 cells
The results obtained on TRF2 protein in compound
treated cells prompted us to study the role of important
complex of proteins (TRF1, TRF2, TIN2 and hTERT)
that are closely associated with telomere stability and
functioning. Here the MCF-7 cells were treated with
chalcone-imadazolone conjugates, RNA was isolated and
RT-PCR analysis has been carried out to observe the
mRNA levels of TRF1, TRF2, TIN2 and hTERT. The
levels of TRF1 and TIN2 were found to be upregulated
in all the compounds tested where as the levels of TRF2
and hTERT was decreased in case of compounds 6 and
8. Thus our data clearly reveals the effect of chalcone
imidazolones on telomeric complex and cause DNA
damage (Figure 12).
Discussion
We have prepared hybrid molecules involving both chal-
cones, the inhibitors of tubulin polymerization and imi-
dazolones, the cytotoxic compounds with the aim of
improving the effective cytotoxicity against various can-
cers that cause mortality of human beings. Breast cancer
is one of the most prevalent cancers in the world and
many are diagnosed with this disease every year [1].
NCI data against these chalocone-imidazolone com-
pounds were tested and found that these compounds
are effective against certain cell lines such as MCF-7
breast carcinoma. Henceforth it is very important to
study these molecules in this cell line. Previous studies
in this laboratory [24] have shown that chalcone-imida-
zolone conjugates cause significant apoptosis at 30 μM
concentration. But in depth molecular mechanism
involved has not been studied.
Cells arrested and which cannot repair DNA damage
would undergo death by processes called as apoptosis or
senescence, a growth arrest phenomena. Apoptosis is a
type of programmed cell death (PCD), the abrogation of
this process leads to carcinogenesis [34,35] and is char-
acterized by membrane blebbing, cell shrinkage, nuclear
condensation and DNA fragmentation [36,37].
Tunel assay clearly revealed the apoptosis inducing
ability of the compounds (6, 8) when compared to con-
trols (Figure 2). More over the cell death due to conju-
gates 6 and 8 was further confirmed by experiments such
as Trypan blue exclusion assay, (Figure 3) which gives
percentage of cell death in a population of cells as well as
membrane blebbing and nuclear condensation which are
the characteristics of apoptosis by DAPI nuclear staining
(Figure 4). Bax and active caspase-9 are crucial regulator
of apoptosis where as cleavage of Rb is the indicator of
apoptosis [25,26]. Our results have shown pronounced
up regulation of Bax protein, cleaved caspase-9 and
cleaved Retinoblastoma (Rb) in the compound treated
cells in comparison to control confirming the apoptotic
inducing nature of the compounds (Figure 5).
P53 is a classical tumor suppressor protein and universal
sensor of genotoxic stress that functions by inhibiting cell
proliferation [38]. In general DNA-damaging agents cause
cell cycle arrest which finally results in apoptosis or
Figure 10 Determination of telomerase activity in chalcone-
imidazolone conjugates treated MCF-7 cells. MCF-7 cells were
treated with 30 μM concentration of chalcone imidazolone
conjugates for 24 h and total cell lysates were subjected to
telomerase specific PCR using fluorescently labeled primers of
TRAPEZE XL telomerase detection kit. The telomerase activity was
measured based on green fluorescence produced due to
fluorescein (F). Internal control primers which are fluorescently
labeled produces red colour which is represented by (R), due to
sulforhodamine. Here TMAC is the starting material used for the
synthesis of chalcone-imidazolone conjugates 6 and 8. CA-4,
Combretastatin is positive control. Fluorescence reading due to
fluorescein (F) was measured with excitation wave length of 495
nm and emission wave length of 516 nm. The fluorescence reading
due to sulforhodamine (R) was measured at excitation wave length
of 600 nm and emission wave length of 620 nm. The F/R ratio gives
the telomerase activity. The p value for each compound was <0.001.
The p value was generated by using student t-test by comparing
the each compound vs control (untreated cells). Each experiment
was conducted in triplicates.
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Page 7 of 12Figure 11 Immunofluorescence based studies of p53BP1 after treatment with chalcone-imidazolone conjugates. MCF-7 Cells were
grown in 10% FBS containing medium on cover slips and treated with 30 μM concentration of chalcone imidazolone compounds (6 and 8).
TMAC, is the starting material and CA-4, is the positive control used. Cells were fixed in 4% paraformaldehyde and processed for
immunofluorescence with p53BP1 antibody as described in materials and methods. Images were captured using confocal microscopy. The
pattern of staining changes was also recorded.
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or independent pathways [27,28]. Our results strongly sup-
port the existence of p53 independent pathway (Figure 6)
and senescence like growth arrest which has been reported
earlier [29]. Studies have shown that Chk2 dependent
senescence as well as transcriptional activation of p21 will
contribute to the tumour suppression in the p53-defective
SK-BR3 breast carcinoma [32]. Thus we have focused our
attention on check point 2 (Chk2) as an alternative
mechanism. Dysfunctional telomeres resulted in phos-
phorylation and activation of Chk2 in ATM dependent
manner which ultimately leads to permanent arrest in cell
cycle which is termed as replicative senescence. There are
also reports that only senescent cells possessed Chk1 and
Chk2 phosphorylated at amino acid residues S345 and
T68 respectively and studies by [33] also suggested that
some of the drugs also can activate Chk1. To concretely
prove the role of check point proteins in the DNA damage
induced senescence, we have checked the levels of the
Chk1 and Chk2 and as well as phosphorylated forms in
the compound treated cells. As expected we found the
levels of the protein were highly upregulated and involve-
ment of these proteins in this event was highly elucidated
(Figure 7)
T h er o l eo fC h k 2i nt h i sD N Ad a m a g ee v e n t
prompted us to check the Telomeric-binding protein 2
(TRF 2), whose inhibition causes apoptosis or senes-
cence at cellular level by causing DNA damage response
[10,32]. Thus we hypothesized that chalcone imidazo-
lone compounds (6 and 8) might have a possible role on
telomeric stability by regulating the expression of TRF2
protein. Hence cell lysates were subjected to western
blotting using TRF2 specific antibody and we found that
the levels of TRF2 were decreased in compound treated
cells (Figure 7). This was further supported by immuno-
localisation studies using TRF2 antibody, where in we
observed, decreased number and as well fusion of TRF2
foci (Figure 8, 9). Thus our results have shown a way to
potentially inhibit proliferation of breast cancer cells
and TRF2 might be effective drug target.
Further we continued our studies on telomerase activ-
i t ya n di t sr o l ei nb r e a s tc ancer progression [9]. We
have experimented towards measuring telomerase activ-
ity in the context of compound treatment. To our sur-
prise down regulation of telomerase activity was
observed in compound 6 and 8 treated cells. Hence the
data strongly supports TRF2 dependent DNA stability
(Figure 10). Previous studies have proved that the
uncapped telomeres are found to be associated with
p53BP1 [30-32]. To ascertain the possible involvement
of p53BP1 in the context of uncapped telomeres MCF-7
cells were treated with compounds (TMAC, CA-4, 6
and 8) and were subjected to immunofluorescence
experiments using p53BP1 specific antibody (Figure 11).
We found the formation of large foci in compound
TMAC, 6 and 8 treated cells, indicating the potential
role of this compound as anti-cancer molecule.
Both in vivo and in vitro studies [12] have shown that
TRF2 inhibition limits cell proliferation of the human
cancer cells and can be considered as an important tar-
get for the development of anti-cancer therapeutics.
TRF1 and TRF2 are the two important molecules which
regulate the telomeric length and DNA damage respec-
tively. TRF1 negatively regulates the telomere length
and TRF2 is actively involved in the protection of telo-
meres. Recent reports have shown that telomere short-
ening triggers senescence which requires the active role
of p21 but does not need p16 activity [39]. The observa-
tions made from the immunolocalisation studies of the
TRF2 have shown the importance of this protein in telo-
meric stability during DNA damage. So we studied the
catalytic subunit of telomere (hTERT) and the impor-
tant telomeric binding proteins such as TRF1, TRF2,
TIN2 and their expression patterns. RT-PCR results
have indicated increased mRNA levels of TRF1 and
TIN2. While the levels of TRF2 and hTERT was
decreased in case of compound 6 and 8 treated cells,
Thus our data clearly reveals the effect of chalcone imi-
dazolones on telomeric complex and cause DNA
damage (Figure 12).
Conclusions
Studies on effect of chalcone imidazolone compounds
on MCF-7 cells identified the apoptotic as well as
Figure 12 mRNA levels of various genes involved in DNA
damage at telomeres in MCF-7 cells. MCF-7 cells were treated
chalcone-imidazolone conjugates at a final concentration of 30 μM
for 24h. After treatment total RNA was isolated and RT-PCR was
conducted. The PCR products were separated on 1% agarose gel
electrophoresis and visualized under U.V light. GAPDH was used as
loading control. Each experiment was repeated three times. The gel
pictures shown here were representative of three independent
experiments.
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of cell cycle arrest the levels of p53, p21 and p16 was
studied. Telomeres binding protein factor 2 (TRF2) as
well p53BP1 that are associated due to DNA damage
initiated telomeric uncapping was highly elucidated.
Certain key molecules that regulate the DNA damage
pathway such as Chk2, Chk2T
68, Chk1and Chk1S
345 was
found to be activated and regulate the senescence as
well as ultimate apoptotic pathway which occurred by
activated levels of Bax, active caspase-9 and cleaved Rb.
This data strongly supports the caspase dependent
apoptotic pathway which was published previously [24].
Ultimately our data has extensively and clearly shown
telomere initiated DNA damage which involves both
senescence like growth arrest and ultimately apoptosis.
Methods
Cell culture
The human breast cancer cell line MCF-7 was pur-
chased from American Type culture collection was
maintained in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) (Invitrogen), supplemented with 10% fetal calf
serum and 100U/ml Pencillin and 100 mg/ml strepto-
mycin sulfate (Sigma). The cell line was maintained at
37°C in a humidified atmosphere containing 5% CO2 in
the incubator.
Tunel assay
T u n e la s s a yw a sc o n d u c t e db yu s i n gt h eA p o a l e r tD N A
fragmentation Assay kit (Clone tech) according to man-
ufacturer instructions. This kit detects the apoptosis-
induced nuclear DNA fragmentation via fluorescence
based assay. The assay is based on the principle of term-
inal deoxy nucleotidyl transferase (TdT)-mediated dUTP
nick-end-labelling (TUNEL) method. TdT catalyzes
incorporation of fluorescein-dUTP at the free 3’-hydro-
xyl ends of fragmented DNA. Flourescein-labeled DNA
can be detected via confocal microscopy.
Immunofluorescence
MCF-7 breast cancer cells were seeded on cover slips
and treated with chalcone imidazolone compounds at
concentration of 30 μM for 24 h. After treatment, cover
slips were fixed with a paraformaldehyde solution (4% in
1X PBS) for 20 min at room temperature. Cell permea-
bilization was achieved by administration of Triton X-
100 solution (0.2% in 1X PBS) for 5 min. Then cover
slips were kept in 100% methanol at 4°C over night.
Subsequently, cover slips were blocked with a 1% BSA
solution for 60 min and then incubated with anti TRF2
and P53BP1 (1:100) antibody at room temperature for 2
h. The slides were washed three times each of 5 min
with PBST. Then cover slips were incubated with a
FITC-conjugated anti-rabbit secondary antibody
(Jackson Immuno Research Laboratories Inc., Pennsylva-
nia, USA) for one hour and cover slips were washed
three times with PBST solution and mounted with
DAPI/PI solution. Finally, cells were observed under
confocal microscope (Olympus FV1000). Images taken
were processed with the support of the flow view ver-
sion 1.7c software program.
TRAPeze XL Telomerase assay
This detection kit (Millipore) is a sensitive as well as
rapid PCR based fluorescent assay for detecting telomer-
ase activity in cell extracts. Treatments were given for 24
h with compounds TMAC, CA-4, 6 and 8 at a concentra-
tion of 30 μM. The cell lysis was carried out using
CHAPS buffer. The extracts were further used for PCR
reaction. Heat inactivated control untreated MCF-7 cell
extract, which lost the telomerase activity is a negative
control as well as control non-heat inactivated cell
extract which has efficient telomerase activity was used
as positive control. Here the telomerase master mix
which contains fluoro labeled primers designed both for
Telomerase as well as internal control TSK2 template
was used along with cell extract and Taq polymerase.
The telomerase activity was measured with green fluores-
cence (F). Internal control amplification pattern was indi-
cated by sulphorhodamine (R), which gives red colour.
The ratio of F and R gives the actual telomerase activity.
The conditions of PCR reaction conditions were followed
according to the manufacturer’s recommendation.
Protein extraction and Western blot analysis
Total cell lysates from cultured MCF-7 cells were
obtained by lysing the cells in ice-cold RIPA buffer
(1XPBS, 1% NP-40, 0.5% sodium deoxycholate and 0.1%
SDS) and containing 100 mg/mL PMSF, 5 mg/mL
Aprotinin, 5 mg/mL leupeptin, 5 mg/mL pepstatin and
100 mg/mL NaF. After centrifugation at 12,000 rpm for
10 min, the protein in supernatant was quantified by
Bradford method (BIO-RAD) using Multimode varios-
kan instrument (Thermo-Fischer Scientifics). Fifty
micrograms of protein per lane was applied in 12%
SDS-polyacrylamide gel. After electrophoresis, the pro-
tein was transferred to polyvinylidine difluoride (PVDF)
membrane (GE Biosciences). The membrane was
b l o c k e da tr o o mt e m p e r a t u r ef o r2hi nT B S+0 . 1 %
Tween20 (TBST) containing 5% blocking powder (San-
tacruz). The membrane was washed with TBST for 5
min, primary antibody was added and incubated at 4°C
overnight (O/N). p53, p21, Chk2, Chk2 T
68, Chk1, Chk1
S
345, Bax, active caspase-9 Cleaved Rb antibodies were
purchased from Imgenex, USA. TRF2 and p53BP1 anti-
bodies were purchased from Cell Signalling Company.
The membrane was incubated with corresponding
horseradish peroxidase-labeled secondary antibody
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Membranes were washed with TBST three times for 15
min and the blots were visualized with chemilumines-
cence reagent (Thermo Fischer Scientifics Ltd.). The X-
ray films were developed with developer and fixed with
fixer solution (Kodak Company Ltd).
Nuclear staining
MCF-7 cells were seeded on cover slips, treated with
compounds for 24 h, washed with PBS and fixed with
4% Paraformaldehyde for 15 min at room temperature.
Fixed cells were incubated in PBS (pH 7.4) containing
DNAse-free RNase (Sigma) for 30 min at 37°C and
stained with DAPI. Nuclear morphology of the cells was
observed under confocal microscope.
Trypan blue exclusion test of cell viability
This method is used to determine the number of viable
cells present in cell suspension. This method is based
on the principle that live cells possess intact cell mem-
branes that excludes trypan blue; whereas dead cells are
not capable of excluding trypan blue. Here viable cells
show a clear cytoplasm where as non viable cells show
blue colour cytoplasm. Compounds were treated for 24
h time period. After compound treatment (TMAC, CA-
4, 6 and 8) at 30 μM concentration the cells were trypsi-
nised and the dead and viable cells were counted. Each
sample was assayed for triplicates. In this assay 10 μlo f
0.4% solution of trypan blue was added to 100 μlo f
cells. Once after mixing the sample was loaded on to
haemocytometer and examined immediately. The per-
centage of dead cells was calculated.
Semi-quantitative reverse transcription PCR (RT-PCR)
Total RNA was extracted using RNeasy mini kit (Qia-
gen, USA) and reverse transcribed into cDNA using
superscript II reverse transcriptase (Invitrogen life tech-
nologies). The PCR was carried out with specific pri-
mers (Table 1) in Takara Bioscience PCR machine. The
products were electrophoresed on agarose gel (1%) fol-
lowed by staining with ethidium bromide and visualized
under U.V. light. The signal intensity of respective
bands was measured by means of the quantity one ver-
sion 4.1.1 soft ware using BIORAD image analysis sys-
tem (CA, USA).
Immunocytochemistry for metaphase spreads
MCF-7 cells were grown in 60 mm dish till 70% con-
fluency. Nocodazole (40 ng/ml) was added 12 h before
the compound treatments (TMAC, CA-4, 6 and 8) at 30
μM final concentration. Treatment with compounds was
carried for 24 h time period. 4-5 h prior to harvest 100
μg/ml colchicine was added. Immediately after treat-
ment cells were washed with PBS and trypsinised. Then
cell pellet was dissolved 0.56% KCl and incubated for 20
min followed by centrifugation at 1000 rpm for 3 min.
Supernatant was discarded. The pellet is flicked and
nuclei solution was added in to funnel and cytospin was
carried out at 1000 rpm for 5-6 min. Slides were
removed and fixed in 4% paraformaldehyde. Slides were
washed with PBS for 15 min and incubated in triton X-
100 and sodium azide solution for 45 min. This is fol-
lowed by addition of 30 μlo fT R F 2a n t i b o d ya n di n c u -
bated overnight at 4°C. The slide is incubated in
blocking solution (goat serum) for 30 min at 4°C. Sec-
ondary antibody was added and incubated for 3 h in
dark at room temperature. Slides were washed for 15
min and incubated with RNaseA (0.5 μg/ml) and
mounted in PI (Vecta shield).
Statistical Analysis
Statistical Analysis was performed using the graph pad
software to evaluate the significant difference between
the control and treated samples. All variables were
tested in three independent experiments. The results
were reported as mean ± SD. * represents p-value <
Table 1 Primer sequences used in Reverse-transcription
polymerase chain reaction (RT-PCR)
S.
NO
Primer Primer Sequence Primer
length
Tm
(
0C)
1. hTERT, Size: 214bp
Sense primer 5’-
cgtggtttctgtgtggtgtc-3’
20 60
Anti sense
primer
5’-
ccttgtcgcctgaggagtag-
3’
20 60
2. TRF2, Size: 160bp
Sense primer 5’-
gtacccaaaggcaagtggaa-
3’
20 59.97
Anti sense
primer
5’-tgacccactcgctttcttct-
3’
20 59.99
3. TRF1, Size:212bp
Sense primer 5’-tctctctttgccgagctttc-
3’
20 59.84
Anti sense
primer
5’-
ggctgattccaagggtgtaa-
3’
20 59.93
4. TIN2, size: 208bp
Sense primer 5’-
ctgagcccatggaacagaat-
3’
20 60.67
Anti sense
primer
5’-tccttatggcctcccctagt-
3’
20 59.92
5. P16, size: 171bp
Sense primer 5’-
gggtcgggtagaggaggtg-
3’
19 61.85
Anti sense
primer
5’-gcgctacctgattccaattc-
3’
20 59.67
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Page 11 of 120.05, ** represents p-value < 0.01, *** represents p-value
< 0.001.
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